Track TB-500 in Peptimes
TB-500 is a peptide of seven amino acids. FDA's substance registry describes it as the "N-terminal acetylated 17-23 fragment of thymosin beta 4". (Source: FDA's substance registry (GSRS).)
Is TB-500 FDA-approved?
No. TB-500 isn't FDA-approved: Drugs@FDA lists no application with TB-500 as an active ingredient.
TB-500
Also: Thymosin Beta-4 Fragment (Ac-LKKTETQ), TB500, N-acetyl-Leu-Lys-Lys-Thr-Glu-Thr-Gln
- Status label in the Peptimes Library
- Not FDA-Approved
- Routes in Peptimes
- SubcutaneousIntramuscular
- Updated
- 25 Oct 2026
US regulatory status
FDA status
Not FDA-Approved. Drugs@FDA lists no application with TB-500 as an active ingredient.
Source: Drugs@FDA, checked 23 Oct 2026
How to track it in Peptimes
The Library has two entries for TB-500, and both show the status label “Not FDA-Approved”. “TB-500” can be logged as subcutaneous or intramuscular. “TB4 Fragment (17-23)” is a separate entry, and it is subcutaneous only. Thymosin beta-4 itself has separate entries. Add the entry that matches your own records in My Protocols, and set the schedule you already follow: days of the week, times of day and a start date. Peptimes never suggests an amount when you log or schedule a dose.
- Logging: the amount you took, the route and how you feel.
- Injection sites: each dose records the site, and Insights shows where you’ve injected and how recently. It never suggests where to inject next.
- Reminders and history: reminders at your times, Dose History, the Calendar and CSV or JSON export work as described on the peptide tracker app page.
Peptimes is a tracking app, not medical advice. Talk to a licensed clinician about your treatment. Peptimes doesn’t sell TB-500 or any other compound.
More sources
- FDA, Global Substance Registration System, TB-500, checked 23 Oct 2026: its sequence of seven amino acids, and the names TB500 and N-acetyl-Leu-Lys-Lys-Thr-Glu-Thr-Gln. “Thymosin Beta-4 Fragment (Ac-LKKTETQ)” is the name the Peptimes Library gives it.
Related pages
Coming soon to the App Store
See planned pricing